Scholars Central

Research articlePublished 30 Apr 2015

Pharmacodynamic comparison of gefitinib plus carboplatin versus gemcitabine plus carboplatin in the treatment of advanced non-small-cell lung carcinoma

Authors: Gennian Mao, Shiyun Zhang, Huihui Song, Xiaoyun Leia, Di Zhu, Haoqian Liu, Chengyuan Liang

Journal of Chemical and Pharmaceutical Research

Volume 7 · Issue 4 · Pages 113–115

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The aim of this study was to explore the clinical efficacy and safety of two different dosage regimens, gefitinib plus carboplatin versus gemcitabine plus carboplatin in the treatment of advanced non-small-cell lung carcinoma (NSCLC). The control group received gemcitabine plus carboplatin treatment while the experimental group received gefitinib plus carboplatin. The result demonstrated that gefitinib plus carboplatin in the treatment of patients with advanced NSCLC was effective and safe, while further clinical investigation should be warranted.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Chemical and Pharmaceutical Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Chemical and Pharmaceutical Research
  • SubjectPharmaceutical Sciences
  • SubjectChemistry
  • BylineArticles whose byline prints “Gennian Mao”
  • BylineArticles whose byline prints “Shiyun Zhang”
  • BylineArticles whose byline prints “Huihui Song”
  • BylineArticles whose byline prints “Xiaoyun Leia”
  • BylineArticles whose byline prints “Di Zhu”
  • BylineArticles whose byline prints “Haoqian Liu”
  • BylineArticles whose byline prints “Chengyuan Liang”